Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : First prospective study for Evexomostat (SDX-7320) , aims to demonstrate that restoring insulin sensitivity in breast cancer patients with baseline insulin resistance will improve clinical outcomes.
Brand Name : SDX-7320
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
LOOKING FOR A SUPPLIER?